Literature DB >> 10759617

The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis.

R Fass1, J J Ofman, R E Sampliner, L Camargo, C Wendel, M B Fennerty.   

Abstract

BACKGROUND: Ambulatory 24-h oesophageal pH monitoring and a short course of high dose omeprazole can be used as diagnostic modalities for GERD. However, comparative studies of the diagnostic accuracy and reliability of both strategies have not been performed. AIM: To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard.
METHODS: Patients with heartburn underwent an upper endoscopy. Only those with erosive oesophagitis were included in the study. Subsequently, patients underwent ambulatory 24-h oesophageal pH monitoring and an 'omeprazole test.' Daily symptoms were recorded during the first week (baseline) and repeated during the second week on therapy (omeprazole 40 mg in the morning and 20 mg in the evening).
RESULTS: Thirty-five patients were included in the study. The omeprazole test was significantly more sensitive in diagnosing GERD than total acid contact time on 24-h oesophageal pH monitoring (83% vs. 60%; P < 0.03). However, the sensitivity of the pH test increased to 80% after adding patients with a positive symptom index, and patients with abnormal acid exposure in the supine or erect positions despite normal total acid contact time. Patients with a normal pH test were significantly younger (49 +/- 2.6 years) than those with abnormal test (59 +/- 1.8; P=0.002).
CONCLUSIONS: In this study an omeprazole test was at least as sensitive as ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in patients with erosive oesophagitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759617     DOI: 10.1046/j.1365-2036.2000.00733.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  26 in total

Review 1.  Endoscopy-negative reflux disease.

Authors:  J P Galmiche; S B des Varannes
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 2.  Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.

Authors:  Joan Monés
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Management of gastro-oesophageal reflux disease: role of proton pump inhibitor test and upper gastro-intestinal endoscopy.

Authors:  M A Bianco; G Rotondano; A Prisco; C Meucci; L Cipolletta
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-10       Impact factor: 2.124

4.  The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications.

Authors:  Jimmy M Bautista; Wai-Man Wong; Gloria Pulliam; Romeo F Esquivel; Ronnie Fass
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

5.  Gastroesophageal reflux disease management according to contemporary international guidelines: a translational study.

Authors:  Fabio Pace; Gabriele Riegler; Annalisa de Leone; Patrizia Dominici; Enzo Grossi
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

Review 6.  Expert consensus document: Advances in the physiological assessment and diagnosis of GERD.

Authors:  Edoardo Savarino; Albert J Bredenoord; Mark Fox; John E Pandolfino; Sabine Roman; C Prakash Gyawali
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

Review 7.  Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.

Authors:  C Prakash Gyawali
Journal:  Curr Gastroenterol Rep       Date:  2017-09

8.  [Antireflux therapy--more than acid reduction?].

Authors:  T Frieling
Journal:  Internist (Berl)       Date:  2004-12       Impact factor: 0.743

Review 9.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 10.  [Bronchopulmonary manifestations of gastroesophageal reflux disease].

Authors:  M V Malfertheiner; A Kandulski; P Malfertheiner; J Schreiber
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.